Terremoto Biosciences Appoints Charles Baum as CEO
Key Highlights Charles Baum, M.D., Ph.D., appointed as Chief Executive Officer of Terremoto Biosciences. Baum succeeds Peter Thompson,…
Browsing Tag
OrbiMed
5 posts
Avenzo Therapeutics Closes $150M Series A-1 Financing
Key Highlights Oversubscribed $150 million Series A-1 financing led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and…
BlossomHill Therapeutics Secures $100M Series B
Key Highlights $100M Series B funding led by Colt Ventures, with notable investors like Cormorant Asset Management and OrbiMed.…
Marc Yoskowitz Takes Helm as CEO at Evozyne to Propel AI-Driven Drug Discovery
Key Highlights Marc Yoskowitz appointed as CEO of Evozyne, bringing extensive leadership from Tempus AI, Pfizer, and McKinsey.…
Odyssey Therapeutics Secures $101 Million in Series C Funding to Propel Immunomodulators and Oncology Medicines
Key Highlights Odyssey Therapeutics, Inc. completes a significant $101 million Series C financing round led by Ascenta Capital. The funding will…